Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439846 | 0.80 | CA1 (0.38) | KDM1AKDM1B | |
| SCHEMBL4078481 | 0.79 | KDM1A (0.31) | RAPGEF4KDM1AKDM1BACHE | |
| SCHEMBL28341279 | 0.79 | RAPGEF4 (0.34) | RAPGEF4KDM1AKDM1BACHE | |
| SCHEMBL21603460 | 0.78 | ALDH1A1 (0.39) | RAPGEF4KDM1AKDM1B | |
| SCHEMBL31088864 | 0.78 | CA1 (0.39) | RAPGEF4 | |
| SCHEMBL29344163 | 0.78 | — | — | |
| SCHEMBL6553501 | 0.77 | CA1 (0.36) | KDM1AKDM1B | |
| SCHEMBL29344166 | 0.75 | SOS1 (0.32) | — | |
| Bromide SCHEMBL10982440 | 0.75 | CA1 (0.35) | KDM1AKDM1B | |
| SCHEMBL823681 | 0.75 | RAPGEF4 (0.38) | RAPGEF4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114085197-A | Synthesis method of 4- (3-trifluoromethylphenyl) -1-piperazine-ethanol, flibanserin intermediate and flibanserin | 合肥创新医药技术有限公司 | 2022-02-25 | — | — | CN | claimed |
| US-7393967-B2 | Process for the preparation of cinacalcet base | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-07-01 | — | — | US | claimed |
| EP-1928817-A1 | PROCESS FOR THE PREPARATION OF CINACALCET BASE | Teva Pharmaceutical Industries Ltd (IL) | 2008-06-11 | — | — | EP | claimed |
| WO-2007127449-A1 | PROCESS FOR THE PREPARATION OF CINACALCET BASE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | WO | claimed |
| US-20070260091-A1 | Process for the preparation of cinacalcet base | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | US | claimed |
| EP-0385835-A1 | Process for the preparation of n-allylmetatrifluoromethylanilin | RHONE-POULENC CHIMIE (FR) | 1990-09-05 | — | — | EP | claimed |
| CN-118619809-B | Preparation method of m-bromobenzotrifluoride | 天门楚天精细化工有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118619809-A | Preparation method of m-bromobenzotrifluoride | 天门楚天精细化工有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-114437269-B | Optical element, optical device, imaging device, and compound | 佳能株式会社 | 2024-06-07 | — | — | CN | disclosed |
| EP-4349828-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Yingli Pharmaceutical Co. Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-114085197-B | Synthesis method of 4- (3-trifluoromethyl phenyl) -1-piperazine-ethanol, flibanserin intermediate and flibanserin | 合肥创新医药技术有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230391785-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, METHOD FOR PREPARING SAME AND USE OF SAME | 280 BIO, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| CN-110462449-B | Optical element, material, optical device and compound | 佳能株式会社 | 2023-08-18 | — | — | CN | disclosed |
| WO-2010004588-A2 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-01-14 | — | — | WO | disclosed |
| US-7393967-B2 | Process for the preparation of cinacalcet base | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-07-01 | — | — | US | disclosed |
| EP-1928817-A1 | PROCESS FOR THE PREPARATION OF CINACALCET BASE | Teva Pharmaceutical Industries Ltd (IL) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007127449-A1 | PROCESS FOR THE PREPARATION OF CINACALCET BASE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | WO | disclosed |
| US-20070260091-A1 | Process for the preparation of cinacalcet base | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | US | disclosed |
| EP-0273528-A1 | Benzophenones and their preparation | Shell Agrar GmbH & Co. KG (DE) | 1988-07-06 | — | — | EP | disclosed |
| US-4038276-A | PROCESS FOR THE PRODUCTION OF FINELY DIVIDED SOLID CYANURIC CHLORIDE | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391785-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, METHOD FOR PREPARING SAME AND USE OF SAME | NRAS, KRAS, REN | RAPGEF4 685/4885KDM1A 3853/4885KDM1B 3812/4885 |
| US-20070260091-A1 | Process for the preparation of cinacalcet base | KRAS, CA9, SI | RAPGEF4 2851/4885KDM1A 1286/4885KDM1B 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.